The mechanisms of ErbB3-mediated resistance to anti-ErbB1/2 monoclonal antibodies, tyrosine kinase inhibitors, and hormonal therapy, and different approaches to its therapeutic targeting in cancer, have been extensively reviewed [11,12,13]. This evidence concerns the gene EGFR and cancer.